Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group’s stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Despite a high P/E ratio compared to peers, investors with a high-risk tolerance may find the IPO appealing.
Positive Breakout: These 13 stocks cross above their 200 DMAs
In the Nifty500 pack, 13 stocks’ closing prices crossed above their 200 DMA (Daily Moving Averages) on March 5, 2026, according to stockedge.com’s technical scan